Sun Pharma ties up with Israeli institute Technion for oncology drug research

Sun Pharmaceutical Industries Ltd has entered into an an exclusive worldwide research and license agreement with Technion - Israel Institute of Technology for cancer treatment drug. This agreement aims to set up a joint project, based on new findings by Nobel Prize laureate distinguished Professor Aaron Ciechanover, Dr Gila Maor and Professor Ofer Binah, that can potentially lead to the development of novel anti-cancer drugs. The pre-clinical research was funded thus far by Dr Alfred Mann.
 
“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this collaboration will help us move rapidly forward with our research. We explored several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us,” said Ciechanover and Binah in a joint statement.
 
They added, “Technion is delighted to partner with Sun Pharma to advance this project through pre-clinical development process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical companies demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship between the Technion and Sun Pharma.”
 
Kirti Ganorkar, senior vice president, business development, Sun Pharma, commented, “This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline. Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs.”